Product Code: RP-ID-10086054 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10086054
Market Overview:
Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023) -- By Region (North America, Europe, APAC), By Country (U.S, Denmark, Germany, Switzerland, Korea, Japan, China) Outlook 2030
"In 2021, the global biopharmaceutical CMO market is estimated to be USD ~30 billion, and it is expected to expand at a compound annual growth rate (CAGR) of ~8% from 2022 to 2030. Increased investment by well-known players in the biopharmaceutical industry to improve its productivity and efficiency has led biomakers to pay more attention to outsourcing activities. Currently, biopharmaceutical companies have begun to outsource resource and capital-intensive steps, and in some cases, even outsource the entire bio-manufacturing chain, thereby driving the demand for contract services. The coronavirus pandemic has disrupted the supply chain of the entire pharmaceutical industry.
However, biopharmaceutical CMOs and CROs have responded well to the epidemic because these organizations are the beneficiaries of supply chain disruptions. CMOs and CROs located in the Western Hemisphere will particularly benefit during the pandemic. For example, the Australian government and Sandoz plan to invest about 50 million euros to promote the production of integrated antibiotics in Europe.Mergers and acquisitions help CMOs provide integrated bioprocessing services to their customers, which in turn makes CMO/CRO an attractive and viable option for rapid product launches. In recent years, the biopharmaceutical industry has seen a lot of consolidation.
These mergers are mainly to expand business and maintain competitiveness in the biopharmaceutical contract manufacturing and service market. Although the CMO & CRO biopharmaceutical industry itself is relatively developed, the initiation and changes of new bioprocessing tools and new therapies take precedence over product-related issues in the bio/pharmaceutical industry, causing bio-contract manufacturers to face greater pressure.
Therefore, CDMO is adopting different business models to meet the needs of customers and stakeholders in the best possible way. In addition, integrating single-use systems into production facilities helps CMOs economically expand manufacturing capabilities. Disposable products provide quick response and restrict related activities such as cleaning and change verification.
SOURCE INFORMATION:
The mammalian part will have the largest share in 2020, at 55%. It is estimated that mammalian cell lines are the main production system for making macromolecules. This is due to its ability to add human-like post-translational modifications to complex protein therapies. Automatic detection method and disposable equipment.
These developments have led to the use of mammalian cells to produce biological products more efficiently. Non-mammalian cell lines, such as microbial cell lines, are considered powerful factories. Innovative strategies are being implemented to identify and explore the potential of various microorganisms. In turn, this is expected to contribute to profitable growth in the non-mammalian biopharmaceutical manufacturing sector.
INFORMATION ON SERVICE TYPE :
The contract manufacturing sector has the largest share in 2020, at 55%. Currently, there are many entities on the market that provide a wide range of services for biopharmaceutical manufacturing. Services range from candidate research and discovery to final product market release. Cultivation services are filled/completed. In addition, customers are investing heavily in the manufacturing aspects of outsourcing their product development plans. These factors have contributed to most of this market segment. GOLD is working hard to take advantage of potential ways in the biopharmaceutical industry. New market entrants and small businesses focused on the development of biopharmaceutical products are expected to select contract research services for their new drug candidate discovery programs, thereby promoting the development of contract research organizations.
PRODUCT INSIGHT:
In 2020, the biologics sector will account for the majority of 80%. Contract services are becoming an increasingly common cost-saving strategy for the efficient and reproducible manufacturing of macromolecules (including biological and biosimilar products). With the increasing popularity of biotherapies for patient care, some traditional drug manufacturers are seeking opportunities to enter the biologics market. Compared with other drug molecules, the high specificity, complicated manufacturing steps and higher success rate of biological agents have led to the dominant position in this field. The use of disposable bioreactors, continuous purification treatment, disposable plastic containers, and real-time quality analysis enable CMOs to meet the growing demand for efficient biological production services.
REGIONAL INFORMATION:
North America has the largest share in 2020, at 34%. CMOs produce a large number of approved products in the United States. Some small and medium-sized biopharmaceutical entities (SMEs) lack the resources and budget to build well-equipped facilities. This, in turn, has increased the interdependence between American CMOs and SMEs, leading to a dominant position in the American market. The Asia-Pacific region is expected to experience significant growth during the forecast period this year. The main reasons for the increase in outsourcing in Asian countries include cost-effectiveness, such as reduced labor and operating costs throughout the region. Due to the country’s high production of macromolecules, India is expected to make significant progress. The lack of global regulatory symmetry in biosimilar approvals has significantly boosted the Indian market. In 2016, India approved 50 biosimilars, of which 24 were approved in Europe and 5 were approved in the United States.
MAJOR COMPANIES AND MARKET SHARE PROSPECTS:
Due to the existence of a large number of mature CMOs and CROs, as well as small and medium-sized scales, this market is inherently fragmented. Some market participants are privately owned or part of the portfolio of private equity companies. Some of the key CMOs in this field are Lonza; Rentschler Biotech Co., Ltd.; Boehringer Ingelheim Co., Ltd.; JRS Pharma (Celonic GmbH); Inno Biologics Sdn Bhd; ProBioGen; BIOMEVA Co., Ltd.; FUJIFILM Diosynth Biotechnologies USA, Inc.; Samsung Bio ; Toyobo Co., Ltd.; CMC Biologics; Patheon; AbbVie; Binex Co., Ltd.; and WuXi Biologics. CMOs are integrating automation and innovative technologies into their factories to improve their capabilities in project performance and product quality.
This has stimulated the interest of macromolecule manufacturers in CMOs to meet the growing demand for biologics. Charles River Laboratory International; PRA Health Sciences; Icon Company; Pharmaceutical Product Development Co., Ltd.; Laboratory Company; Parexel International Corporation is committed to providing contract research services for the production of macromolecules. Some of the major players in the global biopharmaceutical CMO and CRO market include: Boehringer Ingelheim GmbHLonzaInno Biologics Sdn BhdRentschler Biotechnologie GmbH JRS PHARMABIOMEVA GmbHProBioGenFUJIFILM Diosynth Biotechnologies U.S.A., Inc. TOYOBO CO., LTD.Logic CO.Samsung Biotechnologies.
MARKET SEGMENTS COVERED BY REPORT:
The report forecasts global, regional and national revenue growth, and analyzes the latest industry trends and opportunities in each market segment from 2022-2030. For the purpose of this research, Kenneth Research has segmented the global biopharmaceutical CMO and CRO market report based on source, service type, product and region: Source outlook (Revenue, USD million, 2022-2030) Mammal non-mammalian Service type insights (revenue, million dollars, 2022-2030) contract manufacturing process development downstream and upstream filling and completion of operation analysis and quality assurance research packaging contract research oncology inflammation and immunology cardiology neuroscience other dollar biological outlook, 2022-2030 million biological products (revenue, 28 million USD) Monoclonal (MAB). "
Lonza, Boehringer Ingelheium, Samsung Biologics, Wuxi Biologics
Related Reports
Proof of Quality & Reliability
